Literature DB >> 11520041

High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F.

J J Schmidt1, R G Stafford, C B Millard.   

Abstract

Botulinum neurotoxins (BoNT) are zinc metalloproteases that cleave and inactivate cellular proteins essential for neurotransmitter release. Because the paralytic effect of BoNT is a consequence of its enzymatic activity, selective inhibitors may be useful as drugs or as tools for further research. To expedite inhibitor discovery, we developed high-throughput, solid-phase protease activity assays for four of the seven BoNT serotypes: A, B, D, and F. Each assay consisted of a cleavable oligopeptide, based on the natural substrate sequence, labeled with fluorescein and covalently attached to maleimide-activated multiwell plates. Solutions of holotoxin or nontoxic catalytic domain of BoNT were incubated in substrate-coated wells, with or without test compounds, followed by transfer and assay of solubilized product in a multiwell fluorometer. Routine toxin concentrations ranged from 10 to 100 ng/ml, but concentrations as low as 2 ng/ml gave reproducible signals. The fluorescence assays were selective, gave very low background readings, and were stable upon prolonged storage. Using the nontoxic catalytic domain of BoNT A, we determined the relative inhibitory potencies of a family of structurally related pseudotripeptide compounds. Unlike previous methods, our assays did not employ antibodies or reverse-phase extraction steps, only well-to-well transfers, and were easily adapted to a high-throughput automated environment. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520041     DOI: 10.1006/abio.2001.5236

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  32 in total

1.  A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity.

Authors:  Michael Adler; Harlan F Shafer; Heather A Manley; Brennie E Hackley; James D Nicholson; James E Keller; Michael C Goodnough
Journal:  J Protein Chem       Date:  2003-07

2.  Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition.

Authors:  Joseph W Arndt; Wayne Yu; Fay Bi; Raymond C Stevens
Journal:  Biochemistry       Date:  2005-07-19       Impact factor: 3.162

3.  Synaptic vesicle chips to assay botulinum neurotoxins.

Authors:  Géraldine Ferracci; Raymond Miquelis; Shunji Kozaki; Michael Seagar; Christian Lévêque
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 4.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

5.  Comparison of extracellular and intracellular potency of botulinum neurotoxins.

Authors:  Fang Cai; Carrie B Adrion; James E Keller
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

Review 7.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

8.  The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

Authors:  Shuowei Cai; Paul Lindo; Jong-Beak Park; Kruti Vasa; Bal Ram Singh
Journal:  Toxicon       Date:  2009-12-07       Impact factor: 3.033

9.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.